Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$42M, compared with -$32.78M a year earlier.
Context
- Retained earnings amounted to 725.5% of total assets at the end of Q1 FY2026, down 5947.5 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -28.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (41.01M) USD
- Year-over-year change
- -34.0%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (41.01M) | -34.0% |
| FY2024 | 2024-12-31 | (30.6M) | -117.6% |
| FY2023 | 2023-12-31 | (14.06M) | -1317.4% |
| FY2022 | 2022-12-31 | (992.28K) | -618.4% |
| FY2021 | 2021-12-31 | (138.13K) | — |
Retained Earnings vs competitors
How TELO compares with its peers on the latest reported figures
- TELO's Mar 2026 retained earnings of -$42M is the highest of the 6 companies compared; the peer median is -$221.52M.
- Its year-over-year change of -28.1% is the lowest of 6, against a peer median of -12.3%.
- Retained earnings amounts to 725.5% of total assets for TELO, versus a peer median of 575.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$42M | -28.1% | — | 725.5% | |
| Mar 2026 | -$113.87M | -12.0% | — | 575.5% | |
| Mar 2026 | -$214.44M | -24.1% | — | 830.6% | |
| Mar 2026 | -$221.52M | -9.4% | — | 351.2% | |
| Mar 2026 | -$813.56M | -15.3% | — | 249.1% | |
| Mar 2026 | -$1.78B | -12.3% | — | 1355.9% | |
| Peer median (excluding TELO) | -$221.52M | -12.3% | — | 575.5% | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.